Author Affiliations: Division of Pediatric Endocrinology, Department of Pediatrics, B. J. Wadia Hospital for Children Parel, Mumbai 400012, India (Joshi R, Phatarpekar A)

Corresponding Author: Rajesh Joshi, D/3, Om Parshvanath Apartments, Saibaba Nagar, Borivali (West), Mumbai-400 092, India (Tel: +91-022-66916732; Email: rrj23@rediffmail.com)

doi: 10.1007/s12519-011-0254-z

Background: Neonatal diabetes mellitus (NDM) due to KCNJ11 gene mutation presents with diabetes in the first 3 months of life and sometimes with neurological features like developmental delay, muscle weakness and epilepsy.

Methods: A 5-week-old boy presented with diabetic ketoacidosis. Molecular genetic analysis of the patient revealed heterozygous missense mutation, L233F in the KCNJ11 gene, while his mother was mosaic for the same mutation.

Results: The treatment strategy was changed from insulin injections to oral glibenclamide and with a better glycemic control.

Conclusion: The patient with NDM due to mutation L233F (not reported till date) in the KCNJ11 gene can be successfully treated with oral glibenclamide therapy.

Key words: insulin; KCNJ11; neonatal diabetes mellitus   

World J Pediatr 2011;7(4):371-372